Abstract
The healing of gastric ulcer is a complicated process that involves the proliferation of epithelial and endothelial cells and the concerted actions of a wide range of growth factors. Prostaglandins play an important role in ulcer healing. Expression of cyclooxygenase-2 (COX-2) is markedly upregulated around the margins of gastric ulcers and its inhibition leads to a delay of ulcer healing. Several of the growth factors that promote ulcer healing may work in part through COX- 2-dependent mechanisms. Angiogenesis, which is crucial to ulcer healing, is tightly regulated by growth factors. Treatment with selective COX-2 inhibitors appears to alter the balance of serum levels of growth factors, favoring an inhibition of angiogenesis. Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease.
Keywords: ulcer healing, angiogenesis, cyclooxygenase, prostaglandin, endothelium, platelets
Current Pharmaceutical Design
Title: Mucosal Repair and COX-2 Inhibition
Volume: 9 Issue: 27
Author(s): Rafael F. Perini, Li Ma and John L. Wallace
Affiliation:
Keywords: ulcer healing, angiogenesis, cyclooxygenase, prostaglandin, endothelium, platelets
Abstract: The healing of gastric ulcer is a complicated process that involves the proliferation of epithelial and endothelial cells and the concerted actions of a wide range of growth factors. Prostaglandins play an important role in ulcer healing. Expression of cyclooxygenase-2 (COX-2) is markedly upregulated around the margins of gastric ulcers and its inhibition leads to a delay of ulcer healing. Several of the growth factors that promote ulcer healing may work in part through COX- 2-dependent mechanisms. Angiogenesis, which is crucial to ulcer healing, is tightly regulated by growth factors. Treatment with selective COX-2 inhibitors appears to alter the balance of serum levels of growth factors, favoring an inhibition of angiogenesis. Given the importance of COX-2 in regulating ulcer healing, caution should be taken in the use of selective inhibitors of COX-2 by patients at risk of ulcer disease.
Export Options
About this article
Cite this article as:
Perini F. Rafael, Ma Li and Wallace L. John, Mucosal Repair and COX-2 Inhibition, Current Pharmaceutical Design 2003; 9 (27) . https://dx.doi.org/10.2174/1381612033454027
DOI https://dx.doi.org/10.2174/1381612033454027 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry Molecular Functions of BCL10 and MALT1 in Normal and Neoplastic Lymphocytes
Current Immunology Reviews (Discontinued) Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Subject Index to Volume 5
Current Pharmaceutical Biotechnology Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Biodegradable Nanoparticles: A Recent Approach and Applications
Current Drug Targets